<DOC>
	<DOCNO>NCT02254161</DOCNO>
	<brief_summary>The primary objective current study investigate safety tolerability BI 1181181 healthy young male elderly male female volunteer follow oral administration repeat rise dos BI 1181181 , give daily 10 day . Secondary objective exploration pharmacokinetics ( PK ) pharmacodynamics ( PD ) BI 1181181 .</brief_summary>
	<brief_title>Multiple Rising Dose BI 1181181 Given Orally Young Healthy Male Elderly Healthy Male/Female Volunteers</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 . Healthy male female subject accord investigator 's assessment , base complete medical history include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test . 2 . Age 18 50 year ( incl . ) young healthy volunteer 65 80 year ( incl . ) elderly healthy volunteer . 3 . BMI 18.5 29.9 kg/m2 ( incl . ) 4 . Signed date write informed consent prior admission study accordance GCP local legislation . Exclusion criterion : 1 . Any finding medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator 2 . Any laboratory value outside reference range investigator considers clinical relevance 3 . Any evidence concomitant disease judge clinically relevant investigator 4 . Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 5 . Surgery gastrointestinal tract could interfere kinetics trial medication ( except appendectomy ) 6 . Diseases central nervous system ( epilepsy ) , neurological disorder psychiatric disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>